Aleglitazar
Jump to navigation
Jump to search
Aleglitazar is a peroxisome proliferator-activated receptor agonist (hence a PPAR modulator) with affinity to PPARα and PPARγ, which was under development by Hoffmann–La Roche for the treatment of type II diabetes.[1] It is no longer in phase III clinical trials.[2]
References
<templatestyles src="Reflist/styles.css" />
Script error: No such module "Check for unknown parameters".
Script error: No such module "Navbox". Template:PPAR modulators